Annual report
7681.TEDINET S100XACD
Period2024-10-01 → 2025-09-30
Filed2025-12-17
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.5bn | 2024-10-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥19.8bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥26.6bn | 2022-10-01 → 2023-09-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥29.8bn | 2021-10-01 → 2022-09-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥26.3bn | 2020-10-01 → 2021-09-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥288m | 2024-10-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥178m | 2023-10-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥309m | 2024-10-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥181m | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥432m | 2022-10-01 → 2023-09-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥710m | 2021-10-01 → 2022-09-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥596m | 2020-10-01 → 2021-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥309m | 2024-10-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥274m | 2023-10-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥153m | 2024-10-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥136m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥271m | 2022-10-01 → 2023-09-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥437m | 2021-10-01 → 2022-09-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥391m | 2020-10-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥172m | 2024-10-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥155m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥10.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥14.7bn | at 2023-09-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥13.5bn | at 2022-09-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥13.0bn | at 2021-09-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.9bn | at 2024-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.7bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.7bn | at 2023-09-30v | Cons. | Net assets |
| Net assets / equity | ¥5.5bn | at 2022-09-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.2bn | at 2021-09-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.6bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2023-09-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2022-09-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥5.4bn | at 2021-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥87m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥33m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥342m | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥242m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.3bn | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥620m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥101m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥82m | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥50m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥42m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥101m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥97m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥202m | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥121m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥298m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥25.86 | 2024-10-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.09 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.12 | 2022-10-01 → 2023-09-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.3 | 2021-10-01 → 2022-09-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.64 | 2020-10-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥25.76 | 2024-10-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.96 | 2023-10-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥45.84 | 2022-10-01 → 2023-09-30v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.84 | 2021-10-01 → 2022-09-30v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.11 | 2020-10-01 → 2021-09-30d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥951.55 | at 2025-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥943.51 | at 2024-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥946.33 | at 2023-09-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥915.42 | at 2022-09-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥855.78 | at 2021-09-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 51.8% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.9% | at 2023-09-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2022-09-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.8% | at 2021-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.7% | 2024-10-01 → 2025-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2023-10-01 → 2024-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-10-01 → 2023-09-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2021-10-01 → 2022-09-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.0% | 2020-10-01 → 2021-09-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 155 | at 2025-09-30 | Cons. | Number of employees |
| Employees | 170 | at 2024-09-30 | Cons. | Number of employees |
| Employees | 176 | at 2023-09-30v | Cons. | Number of employees |
| Employees | 175 | at 2022-09-30v | Cons. | Number of employees |
| Employees | 162 | at 2021-09-30d | Cons. | Number of employees |
| Revenue | ¥19.5bn | 2024-10-01 → 2025-09-30 | Standalone | Net sales |
| Revenue | ¥17.4bn | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥24.0bn | 2022-10-01 → 2023-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥27.3bn | 2021-10-01 → 2022-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥23.4bn | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥185m | 2024-10-01 → 2025-09-30 | Standalone | Operating income |
| Operating income | −¥40m | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Ordinary income | ¥274m | 2024-10-01 → 2025-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥16m | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥362m | 2022-10-01 → 2023-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥448m | 2021-10-01 → 2022-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥435m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥284m | 2024-10-01 → 2025-09-30 | Standalone | Income before income taxes |
| Profit before tax | ¥77m | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Net income | ¥219m | 2024-10-01 → 2025-09-30 | Standalone | Profit loss |
| Net income | ¥44m | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | ¥269m | 2022-10-01 → 2023-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥294m | 2021-10-01 → 2022-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥297m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥9.9bn | at 2025-09-30 | Standalone | Assets |
| Total assets | ¥9.5bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥13.7bn | at 2023-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.3bn | at 2022-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.7bn | at 2025-09-30 | Standalone | Liabilities |
| Total liabilities | ¥4.3bn | at 2024-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥5.2bn | at 2025-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.1bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.2bn | at 2023-09-30v | Standalone | Net assets |
| Net assets / equity | ¥5.0bn | at 2022-09-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.8bn | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥3.9bn | at 2025-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2024-09-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥37.14 | 2024-10-01 → 2025-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.52 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.7 | 2022-10-01 → 2023-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥49.91 | 2021-10-01 → 2022-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.54 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥37.01 | 2024-10-01 → 2025-09-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.48 | 2023-10-01 → 2024-09-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥45.42 | 2022-10-01 → 2023-09-30v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥49.6 | 2021-10-01 → 2022-09-30v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥50.14 | 2020-10-01 → 2021-09-30d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥17 | 2024-10-01 → 2025-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2023-10-01 → 2024-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2022-10-01 → 2023-09-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-10-01 → 2022-09-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2020-10-01 → 2021-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥885.47 | at 2025-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥865.93 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥884.07 | at 2023-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥853.57 | at 2022-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥818.33 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 52.9% | at 2025-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.0% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2022-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.2% | 2024-10-01 → 2025-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.9% | 2023-10-01 → 2024-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2022-10-01 → 2023-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2021-10-01 → 2022-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,922,000 | at 2025-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,967,800 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,960,800 | at 2023-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,960,800 | at 2022-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,960,800 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 123 | at 2025-09-30 | Standalone | Number of employees |
| Employees | 134 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 137 | at 2023-09-30v | Standalone | Number of employees |
| Employees | 134 | at 2022-09-30v | Standalone | Number of employees |
| Employees | 118 | at 2021-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 61
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2024-10-01 → 2025-09-30 | −¥12,000 |
| Reconciling Itemsreconciling | revenue | 2024-10-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-10-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment assets | at 2025-09-30 | −¥147m |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-09-30 | −¥98m |
| Food Servicereportable segment | capex | 2024-10-01 → 2025-09-30 | ¥2m |
| Food Servicereportable segment | depreciation | 2024-10-01 → 2025-09-30 | ¥3m |
| Food Servicereportable segment | employees | at 2025-09-30 | 10 pure |
| Food Servicereportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥410m |
| Food Servicereportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥410m |
| Food Servicereportable segment | segment assets | at 2025-09-30 | ¥198m |
| Food Servicereportable segment | segment profit | 2024-10-01 → 2025-09-30 | ¥9m |
| Remote Image Diagnosis Service Businessreportable segment | capex | 2024-10-01 → 2025-09-30 | ¥17m |
| Remote Image Diagnosis Service Businessreportable segment | depreciation | 2024-10-01 → 2025-09-30 | ¥16m |
| Remote Image Diagnosis Service Businessreportable segment | employees | at 2025-09-30 | 15 pure |
| Remote Image Diagnosis Service Businessreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥822m |
| Remote Image Diagnosis Service Businessreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥822m |
| Remote Image Diagnosis Service Businessreportable segment | segment assets | at 2025-09-30 | ¥650m |
| Remote Image Diagnosis Service Businessreportable segment | segment profit | 2024-10-01 → 2025-09-30 | ¥69m |
| Total Medical Solution Businessreportable segment | capex | 2024-10-01 → 2025-09-30 | ¥65m |
| Total Medical Solution Businessreportable segment | depreciation | 2024-10-01 → 2025-09-30 | ¥70m |
| Total Medical Solution Businessreportable segment | employees | at 2025-09-30 | 130 pure |
| Total Medical Solution Businessreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥20.3bn |
| Total Medical Solution Businessreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥20.3bn |
| Total Medical Solution Businessreportable segment | revenue intersegment | 2024-10-01 → 2025-09-30 | ¥3m |
| Total Medical Solution Businessreportable segment | segment assets | at 2025-09-30 | ¥10.2bn |
| Total Medical Solution Businessreportable segment | segment profit | 2024-10-01 → 2025-09-30 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-10-01 → 2025-09-30 | ¥85m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-10-01 → 2025-09-30 | ¥90m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-10-01 → 2025-09-30 | ¥21.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-10-01 → 2025-09-30 | ¥21.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-10-01 → 2025-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-09-30 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-10-01 → 2025-09-30 | ¥386m |
| Reconciling Itemsreconciling | depreciation | 2023-10-01 → 2024-09-30 | −¥17,000 |
| Reconciling Itemsreconciling | segment assets | at 2024-09-30 | −¥146m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-09-30 | ¥2m |
| Food Servicereportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥3m |
| Food Servicereportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥416m |
| Food Servicereportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥416m |
| Food Servicereportable segment | segment assets | at 2024-09-30 | ¥191m |
| Food Servicereportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥14m |
| Remote Image Diagnosis Service Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥7m |
| Remote Image Diagnosis Service Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥21m |
| Remote Image Diagnosis Service Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥778m |
| Remote Image Diagnosis Service Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥778m |
| Remote Image Diagnosis Service Businessreportable segment | segment assets | at 2024-09-30 | ¥624m |
| Remote Image Diagnosis Service Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥67m |
| Total Medical Solution Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥37m |
| Total Medical Solution Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥76m |
| Total Medical Solution Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥18.6bn |
| Total Medical Solution Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥18.6bn |
| Total Medical Solution Businessreportable segment | segment assets | at 2024-09-30 | ¥10.0bn |
| Total Medical Solution Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥95m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-10-01 → 2024-09-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-10-01 → 2024-09-30 | ¥100m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-10-01 → 2024-09-30 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-10-01 → 2024-09-30 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-09-30 | ¥10.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-10-01 → 2024-09-30 | ¥176m |
| Total Medical Solution Businessreportable segment | employees | at 2025-09-30 | 123 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,487
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 10 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 9 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 16 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.368 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.002 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.216 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.376 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.518 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.275 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.184 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.537 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.792 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.178 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E34455-000TotalMedicalSolutionBusinessReportableSegmentMember | 130 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E34455-000TotalMedicalSolutionBusinessReportableSegmentMember | 19 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E34455-000RemoteImageDiagnosisServiceBusinessReportableSegmentMember | 15 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E34455-000RemoteImageDiagnosisServiceBusinessReportableSegmentMember | － | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E34455-000FoodServiceReportableSegmentMember | 10 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E34455-000FoodServiceReportableSegmentMember | 49 | |
| Number of employees | CurrentYearInstant | 155 | |
| Average number of temporary workers | CurrentYearInstant | 68 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 123 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 39.2 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 8.9 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6828000 | JPY |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 16 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E34455-000TotalMedicalSolutionBusinessReportableSegmentMember | 123 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E34455-000TotalMedicalSolutionBusinessReportableSegmentMember | 16 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 123 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 16 | |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.211 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 84815000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 5922000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 5922000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 5922000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 5922000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 13 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 15 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 9 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 3 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 468 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 509 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 10 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 1769 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 29620 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 891 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |